I. Introduction Both short-acting and long-acting bronchodilators have been used for many
years for the treatment of asthma and chronic obstructive pulmonary disease (COPD) …

In the UK, diseases that cause airflow obstruction are common. About 5.1 million people
receive treatment for asthma and about 600,000 people are diagnosed as having chronic …

Bronchodilators are still key elements in the treatment of both COPD and asthma and are
likely to remain so for years to come.

Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

Introduction: Inhaled bronchodilators are the mainstay of the current management of COPD
at all stages of the disease, and are critical in the symptomatic management of asthma …

Bronchodilators remain central to the symptomatic management of chronic obstructive
pulmonary disease and asthma, and, for this reason and also because the patent protection …

Chronic obstructive pulmonary disease (COPD) is a leading cause of death and disability.
There is now a better understanding of the pathophysiology of COPD and of the …

Written as a concise clinical reference guide covering the current and future airway disease
treatments, this text encompasses: pathophysiology of respiratory tract diseasesthe methods …

Chronic obstructive pulmonary disease (COPD) is a treatable disease characterized by
progressive airflow limitation. Prevention of disease progression, improvement of symptoms …

Js the approach to bronchodilator therapy for COPD patients about to change course? The
last decade has witnessed a transformation in asthma thempy with more intensive use of …